Figure 2.
Progression-free survival and overall survival from CAR T-cell infusion stratified by prognostic factors. (A) Progression-free survival (PFS) by disease status at lym-phodepletion. (B) PFS by lactate dehydrogenase (LDH) at leukapheresis. (C) PFS by LDH at lymphodepletion. (D) Overall survival (OS) by LDH at leukapheresis. (E) OS by Eastern Cooperative Group performance status (ECOG PS) at lymphodepletion.